Know Cancer

forgot password

An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy

Phase 2/Phase 3
5 Years
Not Enrolling
Hunter Syndrome, Mucopolysaccharidosis II

Thank you

Trial Information

An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy

Study TKT024EXT was conducted in 2 phases. The first phase consisted of a 2-year period with
each year consisting of 52 weekly infusions of idursulfase. Idursulfase was administered to
patients as a continuous IV infusion at a dose of 0.5 mg of protein per kg of body weight
(0.5 mg/kg). Certain final evaluations from Study TKT024 served as the baseline assessments
for this study. Safety and efficacy outcomes were determined at 4-month intervals during the
first year (ie, Weeks 18, 36, and 53) and at 6-month intervals in the second year (ie, Weeks
79 and 105). Safety and clinical outcomes were identical to those evaluated in the
double-blind phase of Study TKT024. Forced vital capacity (FVC) and the 6-minute walk test
(6MWT) continued to be the primary clinical outcomes of this study. Data were also
collected on significant clinical events that reflect disease progression in this patient
population. The focus was on events involving the major organ systems affected by MPS II:
cardiac, respiratory, skeletal, and neurological.

The second phase of the study consisted of weekly infusions of IV idursulfase 0.5 mg/kg and
monitoring patients for safety (via collection of adverse events, concomitant medications,
and vital signs). Patients continued treatment during the second study phase until they
transitioned to commercially available idursulfase or they discontinued this study for other
reasons. Study completion was defined as the time a patient either transitioned to
commercially available idursulfase or discontinued this study for other reasons.

Week 105 defined the beginning of the second study phase. Patients had a scheduled
evaluation every 6 months until they completed or discontinued the study, including a safety
evaluation (assessment of adverse events, concomitant medications, physical examination,
clinical laboratory values, and anti-idursulfase antibodies), measurement of urine GAG
levels, and collection of long-term clinical events. At the time a patient completed or
discontinued the study, the patient should have had an "End of Study" evaluation consisting
of assessment of adverse events, concomitant medications, 12-lead electrocardiogram (ECG),
physical examination (including measurement of height, weight, and head circumference),
clinical laboratory evaluations (including measurement of anti-idursulfase antibodies),
measurement of urine GAG levels, and collection of long-term clinical events. In addition,
patients who discontinued this study for reasons other than transitioning to commercially
available idursulfase had an additional safety assessment 30 days after their last infusion.

To fulfill the secondary objective of this study, a commercial-scale manufacturing lot of
idursulfase was introduced into the trial as soon as it was available, in order to begin
generating safety data on this drug product. Pharmacokinetic (PK) data on this
commercial-scale material was also obtained from the PK studies conducted during the first
year of the study.

Initially, patients continued to receive their weekly infusions at the same study centers as
in Study TKT024. However, based on an acceptable safety experience, patients were
transitioned to investigational centers closer to their homes to receive their infusions.
During the first phase of this study, patients were required to return to the main testing
sites every 4 months during the first year and every 6 months during the second year for
their major study evaluations. During the second phase, patients received their infusions
and had all scheduled evaluations at the local clinical sites.

Inclusion Criteria:

- Patient must have completed the double-blind phase of Study TKT024, defined as
completing the Week 53 final evaluations of the study.

- Patient, patient's parent(s), or legally authorized representative must have
voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee
(IEC)-approved informed consent form after all relevant aspects of the study have
been explained and discussed with the patient, according to the local study site

Exclusion Criteria:

- Patient has received treatment with an investigational therapy other than the study
drug in Study TKT024 within the past 60 days.

- Patient is unable to comply with the protocol (e.g., due to a medical condition such
as cervical cord compression or uncooperative attitude) or is unlikely to complete
the study, as determined by the investigator.

- Patient has experienced an adverse reaction to study drug in Study TKT024, which
contraindicates further treatment with idursulfase.

- Patient with known hypersensitivity to any of the components of idursulfase.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Measurements of the six-minute-walk test (6-MWT) and forced vital capacity (FVC)

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Joseph Muenzer, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of North Carolina, Chapel Hill


United States: Food and Drug Administration

Study ID:




Start Date:

September 2004

Completion Date:

January 2008

Related Keywords:

  • Hunter Syndrome
  • Mucopolysaccharidosis II
  • Hunter syndrome
  • hunters syndrome
  • hunter's syndrome
  • hunter disease
  • hunters disease
  • hunter's disease
  • MPS II
  • MPS2
  • MPS 2
  • mps 2
  • mps ii
  • mucopolysaccharides
  • lysosomal storage disease
  • lysosomal storage disorder
  • chronic ear infection
  • enlarged adenoids
  • mps symptoms
  • mps diagnosis
  • mps ii therapy
  • MPS II therapy
  • MPS II treatment
  • ert treatment
  • elaprase
  • idursulfase
  • iduronate sulfatase
  • iduronate 2 sulfatase
  • enzyme replacement therapy
  • hunter syndrome treatment
  • hunter's syndrome treatment
  • hunter syndrome therapy
  • hunter's disease treatment
  • mps society
  • Mucopolysaccharidoses
  • Mucopolysaccharidosis II



Children's Hospital of Philadelphia Philadelphia, Pennsylvania  19104
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
University of Nebraska Medical Center Omaha, Nebraska  68198-3330
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Franciscan Skemp Healthcare La Crosse, Wisconsin  54601-4796
Children's Hospital Boston Boston, Massachusetts  02115
University of North Carolina at Chapel Hill Chapel Hill, North Carolina  27599
The Children'S Hospital Denver, Colorado  80218
St. Joseph's Hospital Phoenix, Arizona  85013
Pediatric Clinical Research Center, Children's Hospital Oakland Oakland, California  94609
Harbin Clinic Rome, Georgia  30165
Mid-Illinois Hematology and Oncology Associates Normal, Illinois  61761
Saint Louis University Cardinal Glennon Children's Hospital St. Louis, Missouri  63104
Upstate Medical University SUNY Syracuse, New York  13210
Baylor College of Medicine Texas Children's Hospital Houston, Texas  77030
University of Utah Hospital Salt Lake City, Utah  84113